.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,811,120

« Back to Dashboard

Claims for Patent: 5,811,120

Title: Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
Abstract:This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.
Inventor(s): Gibson; Lowell L. (Greenwood, IN), Hartauer; Kerry J. (Indianapolis, IN), Stowers; Julian L. (Indianapolis, IN), Sweetana; Stephanie A. (Bloomington, IN), Thakkar; Arvind L. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/824,590
Patent Claims: 1. A solid administerable pharmaceutical formulation comprising raloxifene hydrochloride in combination with a surfactant, polyvinylpyrrolidone, and a water soluble diluent, wherein:

the surfactant is a sorbitan fatty acid ester or a polyoxvethylene sorbitan fatty acid ester; and

the water soluble diluent is a polyol or sugar.

2. The formulation of claim 1, wherein the surfactant is a polyoxyethylene sorbitan fatty acid ester.

3. The formulation of claim 2, wherein the surfactant is polysorbate 80.

4. The formulation of claim 1, wherein the water soluble diluent is a sugar.

5. The formulation of claim 4, wherein the surfactant is polyoxyethylene sorbitan fatty acid ester.

6. The formulation of claim 5, wherein the sugar is lactose.

7. The formulation of claim 6, wherein the surfactant is polysorbate 80.

8. The formulation of claim 7 further comprising a lubricant and a disintegrant.

9. The formulation of claim 1 further comprising a lubricant and a disintegrant.

10. The formulation of claim 9, wherein the lubricant is magnesium stearate or stearic acid, and the disintegrant is cross-linked polyvinylpyrrolidone.

11. The formulation of claim 10, wherein the surfactant is polyoxyethylene sorbitan fatty acid ester.

12. The formulation of claim 11, wherein the diluent is a sugar.

13. A solid administerable pharmaceutical formulation consisting essentially of raloxifene hydrochloride in combination with a surfactant, polyvinylpyrrolidone, and a water soluble diluent, wherein:

the surfactant is a sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester; and

the water soluble diluent is polyol or sugar.

14. The formulation of claim 13, wherein the surfactant is polyoxyethylene sorbitan fatty acid ester.

15. The formulation of claim 14, wherein the diluent is a sugar.

16. A solid administerable pharmaceutical formulation consisting essentially of raloxifene hydrochloride in combination with polysorbate 80, lactose, polyvinylpyrrolidone, and magnesium stearate.

17. The formulation of claim 8, further comprising a film coating.

18. The formulation of claim 12, further comprising a film coating.

19. The formulation of claim 15, further comprising a film coating.

20. The formulation of claim 16, further comprising a film coating.

21. The formulation of claim 1 wherein said formulation is in the form of a tablet or capsule.

22. The formulation of claim 3 wherein said formulation is in the form of a tablet or capsule.

23. The formulation of claim 8 wherein said formulation is in the form of a tablet or capsule.

24. The formulation of claim 10 wherein said formulation is in the form of a tablet or capsule.

25. The formulation of claim 12 wherein said formulation is in the form of a tablet or capsule.

26. The formulation of claim 13 wherein said formulation is in the form of a tablet or capsule.

27. The formulation of claim 14 wherein said formulation is in the form of a tablet or capsule.

28. The formulation of claim 15 wherein said formulation is in the form of a tablet or capsule.

29. The formulation of claim 16 wherein said formulation is in the form of a tablet or capsule.

30. The formulation of claim 17 wherein said formulation is in the form of a tablet or capsule.

31. The formulation of claim 18 wherein said formulation is in the form of a tablet or capsule.

32. The formulation of claim 19 wherein said formulation is in the form of a tablet or capsule.

33. The formulation of claim 20 wherein said formulation is in the form of a tablet or capsule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc